Resources
7 Results (showing 1 - 7)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 3/25/2021 (updated 4/5/2024)
Stimulants 2021: An Update—Clinical Issues and Treatments
The presenter will review considerations in engaging and treating individuals with stimulant use disorders and present evidence-based treatment strategies relevant to rural communities addressing this growing problem.
Posted 11/17/2021 (updated 4/3/2024)
The National Academies of Science, Engineering, and Medicine defines stigma as a range of negative attitudes, beliefs and behaviors that are associated with certain conditions such as addiction. Dr. Nora Volkow, Director of the National Institute on Drug Abuse (NIDA), has been a leading voice in talking about the “chilling effect” stigma has on our ability to address substance use and addiction in our country. In an April 2020 perspective piece published in the New England Journal of Medicine and in her NIDA blog piece, Dr. Volkow explains how stigma can prevent people from seeking care and can even contribute to their continuing addiction. We encourage our visitors to read Dr. Volkow’s writings as well as to familiarize themselves with the efforts to reduce stigma led by the National Institutes of Health (NIH) including the NIH HEAL InitiativeSM, which has made addressing stigma a key element in their efforts to address opioid addiction.
Posted 8/19/2021 (updated 4/2/2024)
In spring 2021, pharmaceutical manufacturers and distributors notified syringe services programs (SSPs) and partners that there would be significant interruptions in the supply of injectable/intramuscular (IM) naloxone. Currently, production and distribution delays are expected to last until fall 2021. This will specifically affect SSPs because IM naloxone is the most affordable formulation, and therefore is most commonly utilized by programs that distribute large volumes of naloxone to reduce fatal overdose rates.
Posted 7/7/2021 (updated 4/2/2024)
In 2015, 33,091 persons in the United States died from an opioid-related drug overdose.The epidemic of opioid overdose deaths has led to expanding the use of naloxone in community settings by non–medically trained bystanders who are often people who use drugs (PWUD). Since 2013, illicitly manufactured fentanyl (IMF), fentanyl analogs, and other synthetic opioids have played an increasing role in overdose deaths in the United States. Illicitly manufactured fentanyl (IMF) prevalence has increased. However, there is uncertainty about naloxone dose(s) used by nonmedical bystanders to reverse opioid overdoses in the context of increasing IMF.
Posted 9/22/2020 (updated 3/29/2024)
The Post-Overdose Response (PORT) Toolkit was developed as a resource for North Carolina communities who are interested in creating a post-overdose response team (PORT) in their jurisdiction.
Posted 8/11/2020 (updated 3/28/2024)
Sonoran Prevention Works is an advocate for people in Arizona affected by drug use. Spanish language resources from Ssamaritan PAWZ are included.
Posted 7/22/2020 (updated 3/28/2024)
New York State's Opioid Overdose Prevention Program Resources